Men and women aged 18 to 54 with a history of eczema (atopic dermatitis) for at least one year, may qualify to participate in this study. Individuals must have moderate to severe disease, involving 10% or more of their body. To be eligible, participants must also have a recent history of inadequate response to treatment with topical medications.
Participants will receive investigational medication via injection (either active study drug or placebo). One dose each of two vaccines will be administered at one visit during the study. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided.
Study participation will last about 36 weeks and involve about 12 visits to the study clinic. In addition, 2 visits will occur by telephone.
Email Tina Craig, Clincal Research Coordinator at DermEffects to register.